Pool of 252 representative proteotypic peptides for tumor associated antigens derived from 61 annotated human proteins for direct usage in mass-spectrometry based proteomics (MRM).
SpikeMix™ TAA - light - Specifications
Amount: approx. 50-150 pmol per peptide
Purity: crude
Delivery Format: Freeze-dried in plastic vial
Application(s): Proteomics
Condition(s)/Topic(s): Breast cancer, Burkitt's lymphoma, Cancer, Gastric cancer, Malignant genital cancers, Melanoma, Prostate cancer
Standard Delivery Time: 2-5 days
Are you interested in your custom peptide pools for your proteomics assays? Choose your sequence, amount and label. We will assist you along the way. Custom SpikeMix Reference Pools.
JPT's SpikeMix™ TAA
JPT produced a mixture of proteotypic peptides for the detection of the most relevant tumor associated antigens (TAA) by mass-spectrometry based proteomics. Tumor antigens (such as products of mutated oncogenes and tumor suppressor genes or other mutated genes, overexpressed cellular proteins, cell type-specific differentiation antigens) are produced in tumor cells and may trigger an immune response in the host. Tumor antigens are used to identify tumors and are potential candidates for use in cancer therapy. 75 TAAs were selected and prioritized in a NCI pilot project to prioritize cancer antigens (Cheever et al., 2009). For 61 of these TAAs JPT'synthesized proteotypic peptides with well documented MRM transition data available (www.srmatlas.org, ISB). The mixed peptides are available light or isotopically labeled (heavy Arg U-13C6, U-15N4 or Lys U-13C6, U-15N2).
Benefits of JPT's SpikeMix™ TAA
- Quantification of multiple TAA's from a single sample - First economic heavy peptide pool available
- Multiplexed analysis of disease status and therapeutic success
.jpg "SpikeMix™ ABRF (cross-species standard)")